Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Methadone vs placebo CI: confidence interval. · adults with chronic neuropathic pain Methadone for neuropathic pain in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs gabapentin Participant‐reported pain relief of 30% or greater · children and adolescents (birth to 17 years) with chronic non‐cancer pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Citalopram vs placebo Participant‐reported pain relief of 30% or greater · children and adolescents with functional abdominal pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Citalopram vs placebo Participant‐reported pain relief of 50% or greater · children and adolescents with functional abdominal pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Citalopram vs placebo Patient Global Impression of Change: much improved or very much improved · children and adolescents with functional abdominal pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs gabapentin Participant‐reported pain relief of 50% or greater · children and adolescents (birth to 17 years) with chronic non‐cancer pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs gabapentin Patient Global Impression of Change: much improved or very much improved · children and adolescents (birth to 17 years) with chronic non‐cancer pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs placebo Participant‐reported pain relief of 30% or greater · children and adolescents (birth to 17 years) with chronic non‐cancer pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs placebo Participant‐reported pain relief of 50% or greater · children and adolescents (birth to 17 years) with chronic non‐cancer pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Amitriptyline vs placebo Patient Global Impression of Change: much improved or very much improved · children and adolescents (birth to 17 years) with chronic non‐cancer pain Antidepressants for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs amitriptyline Participant‐reported pain relief of 30% or greater · children and adolescents (birth to 17 years of age) with chronic non‐cancer pain Antiepileptic drugs for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs amitriptyline Participant‐reported pain relief of 50% or greater · children and adolescents (birth to 17 years of age) with chronic non‐cancer pain Antiepileptic drugs for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs amitriptyline Patient Global Impression of Change: much improved or very much improved · children and adolescents (birth to 17 years of age) with chronic non‐cancer pain Antiepileptic drugs for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Celecoxib vs naproxen Any adverse event · children and adolescents with chronic non‐cancer pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Rofecoxib vs naproxen Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Rofecoxib vs naproxen Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Meloxicam vs naproxen Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Celecoxib vs naproxen Participant‐reported pain relief of 50% or greater · children and adolescents with chronic non‐cancer pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Celecoxib vs naproxen Patient Global Impression of Change much or very much improved · children and adolescents with chronic non‐cancer pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · children (aged 6 to 11 years) being overweight or obese Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · children (aged 6 to 11 years) being overweight or obese Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Socioeconomic effects · children (aged 6 to 11 years) being overweight or obese Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from… (2017) · Cochrane | no estimate extracted | NR | No studies |
Bilateral vs unilateral hearing aids Hearing‐specific HRQL · adults with hearing loss Bilateral versus unilateral hearing aids for bilateral hearing impairment in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Bilateral vs unilateral hearing aids Adverse effects: pain or discomfort in the ear, initiation or exacerbation of middle or outer ear infection · adults with hearing loss Bilateral versus unilateral hearing aids for bilateral hearing impairment in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Bilateral vs unilateral hearing aids Generic HRQL ‐ not measured · adults with hearing loss Bilateral versus unilateral hearing aids for bilateral hearing impairment in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Bilateral vs unilateral hearing aids Listening ability · adults with hearing loss Bilateral versus unilateral hearing aids for bilateral hearing impairment in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · adolescents (aged 12‐17 years) being overweight or obese Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · adolescents (aged 12‐17 years) being overweight or obese Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents… (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Socioeconomic effects · adolescents (aged 12‐17 years) being overweight or obese Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents… (2017) · Cochrane | no estimate extracted | NR | No studies |
Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg Recovery timea from post‐tetanic count (PTC) · adult patients, ASA I to IV, who received non‐depolarizing NMBAs Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Sugammadex 2.0 mg/kg vs neostigmine 0.05 mg/kg Risks of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · adult patients, ASA I to IV, who received non‐depolarizing NMBAs Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · adult patients, ASA I to IV, who received non‐depolarizing NMBAs Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Sugammadex 4.0 mg/kg vs neostigmine 0.07 mg/kg Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · adult patients, ASA I to IV, who received non‐depolarizing NMBAs Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Sugammadex (any dose) vs neostigmine (any dose) Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Sugammadex (any dose) vs neostigmine (any dose) Recovery timea from post‐tetanic count (PTC) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs ultrasound Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS:SSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Overall improvement in CTS: FSS: long term · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs fascial manipulation Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS:SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs ultrasound and a splint Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy and a splint vs placebo and a splint Overall improvement in CTS: FSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: SSS: long term ‐ not measured · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Overall improvement in CTS: FSS: long term ‐ not reported · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy, wrist splint, and vitamin B6 vs placebo, wrist splint, and vitamin B6 Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Low‐level laser therapy vs placebo Adverse events · carpal tunnel syndrome Low‐level laser therapy for carpal tunnel syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Venalot Depot (coumarin plus troxerutin) vs Placebo Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy (2017) · Cochrane | No data on either quality of life or other oral related symptoms were reported. | 0 studies | No studies |
ART using composite resin vs Conventional treatment using composite resin Secondary caries · Children with dental caries in primary teeth (mean age 7 years) Atraumatic restorative treatment versus conventional restorative treatment for managing dental caries (2017) · Cochrane | No studies reported on secondary caries for this comparison. | 0 studies | No studies |